Two Directors at Starpharma Holdings Limited bought 755,886 shares at between 0.096AUD and 0.098AUD. The significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's direct...
Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked....
MELBOURNE, Australia--(BUSINESS WIRE)-- Starpharma (ASX: SPL, OTCQX: SPHRY) today announced that its US New Drug Application (NDA) submission for VivaGel® BV for both treatment and prevention of BV has been lodged with the FDA through a rolling submission process. VivaGel® BV has been granted Fast Track status and Qualified Infectious Disease Product (QIDP) designation, which allows for rolling submission of the NDA and ensures priority regulatory review by the FDA. FDA Fast Track status is designed to accelerate the...
MELBOURNE, Australia--(BUSINESS WIRE)-- Starpharma (ASX: SPL, OTCQX: SPHRY) today announced that its two phase 3 trials of VivaGel® BV for prevention of recurrent bacterial vaginosis (rBV) achieved their primary objective demonstrating statistically significant superiority compared to placebo in preventing rBV based on topline data. Starpharma intends to submit a marketing application to the FDA for VivaGel® BV for prevention of rBV based on these positive results. There are currently no approved products for the prevention o...
MELBOURNE, Australia--(BUSINESS WIRE)-- Starpharma Holdings Ltd (ASX: SPL, OTCQX: SPHRY) today announced that it has completed a transaction to sell its agrochemicals and Priostar® business (Starpharma Agrochemicals) to Agrium, Inc., (Agrium) (NYSE: AGU, TSE: AGU) for A$35 million in cash consideration. The Starpharma Agrochemical business will be operated by Agrium’s wholly-owned subsidiary, Loveland Products, Inc. Starpharma Agrochemicals is comprised of key patents and technical know-how as well as a small number of staff ...
MELBOURNE, Australia--(BUSINESS WIRE)-- Starpharma Holdings Ltd (ASX:SPL, OTCQX:SPHRY) is pleased to announce the VivaGel® condom has been launched in Canada by Ansell (ASX:ANN) under the LifeStyles® Dual Protect™ brand. These condoms carry the VivaGel® brand and Starpharma will receive royalties based on sales. Ansell is a global leader in protection solutions and the makers of LifeStyles® and SKYN® Condoms (“SKYN”) brands. The LifeStyles® Dual Protect™ condom is a world-first product based on innovative Aust...
MELBOURNE, Australia--(BUSINESS WIRE)-- Starpharma Holdings Ltd (ASX:SPL, OTCQX:SPHRY) today announced it has been granted Qualified Infectious Disease Product (QIDP) and Fast Track designation for VivaGel® BV by the US Food and Drug Administration (FDA). QIDP and Fast Track designations were granted independently for both the VivaGel® BV treatment and prevention indications for bacterial vaginosis (BV). This positive development recognises the high unmet medical need in the management of BV and the potential of VivaGel® ...
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind...
MELBOURNE, Australie--(BUSINESS WIRE)-- Starpharma Holdings Ltd (ASX :SPL)(OTCQX :SPHRY) a annoncé aujourd'hui la délivrance d'un brevet par le Bureau américain des brevets pour une formulation du glyphosate Priostar®. La période de validité du brevet est prévue pour durer jusqu'en 2030, accordant une extension des brevets Priostar® délivrés existants. Une duréesupplémentaire peut également être disponible en cas de retard du bureau des brevets et de l'approbation réglementaire. Ce brevet ajoute une valeur supplémentaire au p...
MELBOURNE, Australia--(BUSINESS WIRE)-- Starpharma Holdings Ltd (ASX:SPL)(OTCQX:SPHRY) today announced the allowance of a patent by the US Patent Office for a Priostar® glyphosate formulation. The patent’s term is expected to be to 2030 providing an extension over existing granted Priostar® patents. Additional term may also be available in relation to patent office delay and regulatory approval. This patent adds further value to the Priostar® patent portfolio which comprises granted patents in key markets, including in ...
MELBOURNE, Australia--(BUSINESS WIRE)-- Starpharma Holdings Ltd (ASX: SPL) (OTCQX: SPHRY) today announced it had been granted a medical device license for the VivaGel® condom by the Canadian regulatory authority, Health Canada. Starpharma’s marketing partner, Ansell (ASX: ANN), plans to launch the VivaGel® condom in Canada as soon as possible under the LifeStyles® Dual Protect™ brand. The VivaGel® condom is a world-first product based on innovative Australian technology. It is the only condom of its type, prov...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.